ArticleMicrobiology spectrum2025
Predictive value of hepatic, hematological, and immunological markers and their temporal dynamics in chronic hepatitis B functional cure.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Hemostasis: Platelet Biomarkers and Vascular-Immune Crosstalk in Dengue.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Construction and validation of a predictive model for HBsAg loss in chronic hepatitis B patients treated with Peg-IFNα-2b.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) infection remains a major global health burden. While interferon-alpha (IFNα) therapy demonstrates antiviral and immunomodulatory effects, reliable prognostic markers for sustained response are needed. Transaminases, hematological parameters, and cytokines may serve as potential predictors, but their dynamic changes during IFNα therapy remain poorly characterized. In this prospective real-world study, 181 chronic HBV (CHB) patients received weekly PEG-IFNα-2b for 48 weeks, with serial assessments of virological (HBV DNA, hepatitis B surface antigen [HBsAg]), biochemical (alanine aminotransferase [ALT], aspartate aminotransferase [AST]), hematological (white blood cell [WBC], platelets), and cytokine (interleukin [IL]-4/6, tumor necrosis factor-alpha [TNF-α], IFN-γ) profiles every 4 weeks. The primary outcome was functional cure of CHB. Statistical analyses included (i) generalized linear models (GLMs) evaluating associations between cure status and predictor trends; (ii) Cox regression identifying prognostic factors; (iii) trajectory clustering of biomarker dynamics. Results indicated that sustained declines in ALT (β = -0.025,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.